Endocrinology  ·  Women's Health

PCOS Has Been Renamed PMOS — What This Means for Patients

Dr Syed Kashif Hussain Kazmi | Consultant Endocrinologist | Updated July 2026 | ~19 min read
← Back to Blog

For decades, millions of women have been diagnosed with Polycystic Ovary Syndrome — a name that carries with it a set of deeply misleading implications. The word "cysts" causes immediate alarm when there are no cysts involved. The word "ovary" implies the problem is confined to the reproductive organs when it is, in fact, a whole-body metabolic disorder. And the word "syndrome" has long obscured the condition's complexity, severity, and lifelong consequences. Following a 14-year global consensus process involving 56 professional and patient organisations and more than 22,000 stakeholders, the condition has now been formally renamed PMOS — Polyendocrine Metabolic Ovarian Syndrome, published in The Lancet in May 2026. This article explains what the name change means, why it matters, how the diagnostic criteria stand today, and what it changes about clinical management and patient experience.

Why the Old Name Was Always a Problem

The term "Polycystic Ovary Syndrome" has been in use since 1935, when Stein and Leventhal described a group of women with enlarged, cystic-appearing ovaries, irregular periods, and signs of androgen excess. The name stuck. For 90 years, clinicians and patients alike have used it — even as the medical understanding of the condition evolved far beyond what the original name suggested.

The fundamental problem is that PCOS is not a disease of cysts. What appears on ultrasound as polycystic morphology is not the presence of true ovarian cysts — fluid-filled sacs with a wall and contents. Instead, what is seen is an unusually large number of small antral follicles, each containing a developing egg that has failed to reach full maturity and ovulate. These follicles are the result of a disrupted hormonal environment, not cyst formation. They are a consequence of the condition, not its cause.

Furthermore, the ovaries are not even the primary site of pathology. The condition is rooted in insulin resistance and androgen excess — metabolic abnormalities that affect the liver, adipose tissue, skeletal muscle, the adrenal glands, and the hypothalamic-pituitary axis. Calling it an ovarian syndrome is akin to calling type 2 diabetes a "pancreatic syndrome" — technically touching on one organ involved, while missing the systemic nature of the disorder entirely.

Why Terminology Matters for Patients

Multiple qualitative studies have documented that the word "cysts" causes significant anxiety and distress in newly diagnosed patients, many of whom believe they have dangerous ovarian growths that will require surgery. A 2020 survey published in Human Reproduction found that more than 60% of women with PCOS reported that the name itself contributed to misunderstanding of their condition — both in themselves and in family members, partners, and employers. Renaming the condition to PMOS removes the most damaging element of the old terminology: the implication of cystic disease.

Two Milestones: The 2023 Diagnostic Update and the 2026 Renaming

It helps to separate two distinct events that patients often conflate. In 2023, ESHRE, together with the American Society for Reproductive Medicine (ASRM) and other partner societies, published an updated international evidence-based guideline on PCOS diagnosis and management — the work of over 80 international experts, and the most comprehensive update to PCOS clinical guidance in over a decade. Separately, in May 2026, the condition itself was formally renamed following a much longer, independent global consensus process. The clinical criteria below come from the 2023 guideline; the new name comes from the 2026 consensus.

May 2026: PCOS Is Formally Renamed PMOS

On 12 May 2026, The Lancet published the outcome of a 14-year global consensus process, led by the International PCOS Network under Professor Helena Teede, involving 56 professional and patient organisations across six continents and feedback from over 22,000 stakeholders — the largest initiative ever undertaken to rename a medical condition. The final survey alone captured responses from 14,360 people (10,411 with the condition, 3,949 healthcare professionals), with 85.6% of patients and 76.1% of health professionals supporting a name change.

The condition has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). Each word is deliberate: "polyendocrine" reflects that multiple hormone systems are involved, not just the ovaries; "metabolic" names the insulin resistance and cardiometabolic risk that drive much of the condition's long-term impact; "ovarian" retains the link to ovulatory dysfunction without implying pathological cysts. As Professor Teede put it, there is "no increase in abnormal cysts on the ovary," and the old name's focus on cysts left the condition's other features — and its patients — "heart-breaking[ly]" under-recognised, with delayed diagnosis and inadequate care.

This is a naming change, not (yet) a change to diagnostic criteria. The Rotterdam 2-of-3 framework and the 2023 diagnostic thresholds described below remain the clinical standard for now. A three-year transition period began in May 2026, during which guidelines, patient records, and clinical education will gradually adopt "PMOS." Any resulting refinements to diagnostic criteria are expected to be formally incorporated into the next International Guideline update, due in 2028. Patients should not be alarmed if their GP or a specialist still uses "PCOS" for some time yet — the underlying condition, its management, and its implications are unchanged; only the name and the framing around it have changed.

2023: Updated Ultrasound Diagnostic Threshold — Still the Operative Standard

The ESHRE 2023 guideline introduced a critical change to the ultrasound criterion for diagnosing polycystic ovarian morphology. The old threshold, established in the 2003 Rotterdam consensus, defined PCOM as ≥12 follicles (2–9 mm diameter) per ovary, or ovarian volume ≥10 ml. This threshold was set in an era of lower-resolution ultrasound technology.

Modern high-frequency transvaginal probes can now identify significantly more follicles than earlier equipment. Using the old threshold of ≥12 follicles with a contemporary probe would lead to massive over-diagnosis — many women with normal ovarian morphology would be labelled as having PCOM. The 2023 guideline therefore updated the follicle count threshold to:

Updated PMOS Ultrasound Criterion (ESHRE 2023)

≥20 follicles per ovary (using a high-frequency probe ≥8 MHz) or ovarian volume ≥10 ml on either ovary — in the absence of a dominant follicle, cyst, or corpus luteum.

The follicle count criterion applies only when using modern high-resolution equipment. If only a lower-frequency probe is available, ovarian volume ≥10 ml per ovary should be used as the criterion.

This update means that some women who were previously diagnosed with PCOS based on polycystic morphology alone — using older equipment and the ≥12 follicle threshold — may no longer meet the revised ultrasound criterion. However, the diagnosis of PMOS requires only 2 of the 3 Rotterdam criteria; polycystic ovarian morphology on ultrasound is just one element. Women with clinical or biochemical hyperandrogenism and irregular cycles retain their diagnosis regardless of the updated ultrasound threshold.

The Three Diagnostic Criteria: Rotterdam Retained

The 2023 guideline retains the foundational Rotterdam 2-of-3 diagnostic framework but refines how each criterion is applied. A diagnosis of PMOS requires the presence of at least two of the following three features, after exclusion of other causes:

Criterion How It Is Assessed (2023 Update)
Oligo/anovulation
(irregular or absent ovulation)		 Menstrual cycles <21 days or >35 days, or fewer than 8 cycles per year. In the first year following menarche, cycle irregularity is normal and should not be used diagnostically. In perimenopause, cycle variability alone is insufficient.
Clinical or biochemical hyperandrogenism Clinical: hirsutism (modified Ferriman-Gallwey score ≥4–6 depending on ethnicity), acne (moderate-severe), or androgenic alopecia. Biochemical: elevated total or free testosterone; DHEAS; androstenedione. LC-MS/MS is the preferred assay. SHBG should be measured to calculate free androgen index (FAI = total T × 100 / SHBG).
Polycystic ovarian morphology (PCOM) ≥20 follicles per ovary (high-resolution probe ≥8 MHz) or ovarian volume ≥10 ml per ovary. AMH (anti-Müllerian hormone) may support PCOM diagnosis but is not yet a standalone criterion.

Conditions that must be excluded before diagnosing PMOS include: congenital adrenal hyperplasia (17-OHP), thyroid dysfunction (TSH), hyperprolactinaemia (prolactin), Cushing's syndrome (if clinically suspected), and androgen-secreting tumours (if testosterone is markedly elevated, typically >5 nmol/L).

The Four Phenotypes: Not All PMOS Is the Same

One of the most clinically important but commonly overlooked aspects of PMOS is that it is phenotypically heterogeneous. Based on which of the three Rotterdam criteria are present, four distinct phenotypes are recognised. The phenotype significantly influences metabolic risk and guides the intensity of screening and intervention.

Phenotype Features Present Metabolic Risk
A (Classic) Hyperandrogenism + Anovulation + PCOM Highest. Insulin resistance, dyslipidaemia, elevated cardiovascular risk.
B Hyperandrogenism + Anovulation (no PCOM) High. Similar metabolic profile to Phenotype A.
C Hyperandrogenism + PCOM (regular cycles) Intermediate. Androgen excess is present but ovulatory function maintained.
D (Non-androgenic) Anovulation + PCOM (no hyperandrogenism) Lower but not absent. Important: metabolic screening still warranted.

This phenotypic classification has direct implications for management. A woman with Phenotype A should be screened more aggressively for insulin resistance, prediabetes, dyslipidaemia, and cardiovascular risk factors than a woman with Phenotype D. Treating all PMOS patients identically is a clinical error.

The Metabolic Reality of PMOS

One of the most important shifts in the 2023 guidelines is the explicit recognition that PMOS is primarily a metabolic condition, not simply a reproductive one. This reframing has profound implications for how the condition is managed across a patient's lifetime — well beyond the reproductive years.

Insulin Resistance: The Central Pathology

Insulin resistance is present in approximately 70–80% of women with PMOS, irrespective of BMI. In the hyperinsulinaemic state that follows, the ovaries — uniquely sensitive to insulin — produce excess androgens. The liver responds by reducing its production of sex hormone-binding globulin (SHBG), which further increases free androgen bioavailability. The pituitary, under the influence of elevated androgens and disrupted negative feedback, increases LH pulse frequency, which stimulates further ovarian androgen production. This creates a self-reinforcing cycle of androgen excess, follicular arrest, and anovulation.

The key clinical implication: treating insulin resistance is treating the root of PMOS. Lifestyle interventions, metformin, and — increasingly — GLP-1 receptor agonists all work in part by improving insulin sensitivity.

Long-Term Metabolic Risks

Women with PMOS face substantially elevated lifetime risks across several domains:

Mental Health: The Under-Recognised Burden

The 2023 guideline places unprecedented emphasis on mental health screening as a mandatory component of PMOS assessment. Women with PMOS have a 3–4× increased risk of depression and anxiety compared to women without the condition. This excess is driven by multiple factors: the symptom burden (hirsutism, acne, weight gain, irregular periods), the impact of infertility concerns, the history of delayed or incorrect diagnoses, and possibly neurobiological effects of androgen excess and insulin resistance on the central nervous system.

Mandatory Mental Health Screening in PMOS

ESHRE 2023 recommends that all women with PMOS are routinely screened for depression, anxiety, body image concerns, and disordered eating at diagnosis and at subsequent reviews. The PHQ-9 (depression), GAD-7 (anxiety), and specific body image questionnaires should be used systematically, not only when symptoms are volunteered. Referral to psychology or psychiatry should be made without hesitation when screening is positive.

Body dysmorphia, disordered eating, and binge eating disorder are also over-represented in PMOS and can be profoundly worsened by clinical approaches that focus exclusively on weight loss without addressing psychological wellbeing.

Treatment in the PMOS Era

The ESHRE 2023 guideline provides an updated evidence hierarchy for treatment. The key shift is from a reproductive-centric model ("manage the periods and help with fertility") to a comprehensive metabolic management model that addresses weight, insulin resistance, cardiovascular risk, and mental health as primary treatment targets — not secondary afterthoughts.

Lifestyle Intervention: Still First-Line

A sustained weight loss of 5–10% of body weight in women with overweight or obesity reduces androgen levels, restores ovulatory function in a significant proportion, improves insulin sensitivity, and reduces cardiovascular risk. This degree of weight loss is the single most effective intervention available for PMOS in women with excess weight, yet it is also the most difficult to achieve and maintain without clinical support.

The 2023 guideline emphasises that lifestyle advice must be delivered in a non-stigmatising, individualised way that acknowledges the physiological barriers to weight loss in PMOS. Women with PMOS have intrinsically higher appetite-driving signals, lower basal metabolic rates relative to fat mass, and greater difficulty with weight maintenance compared to women without the condition — even at equivalent caloric intake. Telling a patient simply to "eat less and exercise more" is both clinically insufficient and psychologically harmful.

Strength and resistance training is particularly beneficial in PMOS: it builds metabolically active muscle mass, improves insulin sensitivity at the muscular level, and reduces visceral adiposity without the hormonal consequences of extreme caloric restriction.

Metformin: Broader Indications

Metformin is recommended by ESHRE 2023 for metabolic and reproductive benefits in PMOS regardless of BMI. Its primary mechanism is reducing hepatic glucose output and improving peripheral insulin sensitivity. In PMOS specifically:

Standard dosing begins at 500 mg once daily with evening meal, increasing weekly to a target of 1500–2000 mg daily in divided doses. Gastrointestinal side effects (nausea, diarrhoea) are common at initiation and largely resolve with gradual dose escalation and food co-administration. The slow-release (XR) formulation is significantly better tolerated and is preferred in patients with gastrointestinal sensitivity. Metformin requires normal renal function (eGFR >45 ml/min/1.73m²) and annual monitoring of B12, as prolonged use can deplete B12 stores.

GLP-1 Receptor Agonists: Emerging Evidence in PMOS

GLP-1 receptor agonists — semaglutide (Ozempic/Wegovy) and liraglutide (Victoza/Saxenda) — are generating significant interest in PMOS management. Their role is not yet established in formal guidelines as a first-line PMOS treatment, but the evidence base is rapidly expanding.

In women with PMOS and overweight or obesity, GLP-1 RAs produce substantially greater weight loss than lifestyle intervention or metformin alone. The SELECT trial (2023) demonstrated 17.4% mean weight loss with semaglutide 2.4 mg weekly versus placebo over 68 weeks in non-diabetic individuals with overweight and cardiovascular disease — a degree of weight loss not previously achievable without bariatric surgery. Early PMOS-specific trials show improvements in menstrual regularity, androgen levels, and markers of insulin resistance with GLP-1 RA treatment, though larger randomised controlled trials specifically in PMOS populations are ongoing. SURMOUNT-1, 2023

In clinical practice, GLP-1 RAs should be considered in women with PMOS and:

Patient Safety Warning: Unregulated GLP-1 Acquisition in PMOS

The dramatic weight loss outcomes reported with GLP-1 RAs have driven a significant increase in self-administration of these medications obtained online without medical supervision — a particularly concerning trend in the PMOS population. Women with PMOS who are trying to conceive face specific risks from unsupervised use: GLP-1 RAs cross the placenta and are contraindicated in pregnancy. Improved metabolic health and weight loss from GLP-1 RAs can restore ovulation unexpectedly, increasing the risk of an unplanned pregnancy while on a teratogenic medication. All GLP-1 RA prescribing in women of reproductive age must include contraception counselling and clear pre-conception cessation planning.

Inositol: An Evidence-Based Supplement

Inositol — specifically the combination of myo-inositol and D-chiro-inositol in a 40:1 ratio — has a growing evidence base in PMOS. Inositols are insulin second-messengers; reduced inositol signalling contributes to insulin resistance and impaired follicular development in PMOS. Supplementation at doses of 2–4 g myo-inositol daily has been shown in multiple randomised controlled trials to:

Inositol is not a licensed medication and is classified as a food supplement in Ireland and the UK. It is not yet included in ESHRE 2023 as a formal treatment recommendation, but is acknowledged as having a favourable safety profile and may be considered as an adjunct to lifestyle intervention, particularly in women who do not tolerate metformin or who prefer not to take prescription medications initially.

Combined Oral Contraceptive Pill (COCP): Updated Guidance

The COCP remains a first-line pharmacological option for women with PMOS who require contraception, menstrual cycle regulation, or management of androgenic symptoms (hirsutism, acne). It acts by:

The ESHRE 2023 guideline emphasises that COCP choice matters in PMOS. Pills containing anti-androgenic progestogens — drospirenone (Yasmin, Eloine), cyproterone acetate (co-cyprindiol/Dianette), or dienogest — are preferable to pills with androgenic progestogens such as levonorgestrel or norethisterone, which can partially negate the androgen-lowering benefit and may worsen acne and hirsutism. Drospirenone-containing pills offer the additional benefit of anti-mineralocorticoid activity, which may reduce bloating and fluid retention.

Women should understand that the COCP manages symptoms but does not treat the underlying metabolic pathology. It masks menstrual irregularity and androgen excess, but insulin resistance and its consequences persist and require independent metabolic management.

Ovulation Induction: Letrozole as Preferred Agent

For women with PMOS who wish to conceive and are anovulatory, ovulation induction is required. The 2023 guideline unambiguously positions letrozole (an aromatase inhibitor) as the first-line agent for ovulation induction in PMOS, superseding clomiphene citrate (clomifene). This represents a significant change from older practice.

Letrozole produces higher ovulation rates, higher live birth rates, and a lower rate of multiple pregnancy compared to clomiphene in PMOS — as demonstrated in the landmark ESPART trial and confirmed in multiple subsequent meta-analyses. Legro RS, NEJM 2014 Letrozole is administered for 5 days in the early follicular phase, with ultrasound monitoring to confirm follicular development and timing of intercourse or insemination.

Clomiphene may still be used where letrozole is unavailable or not tolerated, but it is no longer the preferred first step. Women who fail to ovulate on letrozole alone may benefit from the addition of metformin, which enhances ovulation induction response.

What Does the Rename Mean Practically for Current Patients?

If you have been diagnosed with PCOS, you do not need to do anything differently. Your diagnosis is not being invalidated; the underlying condition remains the same. The name change is a medical community process that will filter into clinical practice progressively over the coming years. What you should understand is that this rename reflects a more accurate, less stigmatising understanding of your condition — one that acknowledges:

When to Seek a Specialist Review for PMOS

You should seek an endocrinology review if:

  • Your PMOS diagnosis has not included metabolic screening (glucose, lipids, blood pressure)
  • Your periods remain irregular despite treatment
  • Hirsutism, acne, or hair loss is significantly affecting your quality of life
  • You have been trying to conceive for 6 months without success
  • You have prediabetes or type 2 diabetes alongside PMOS
  • Your testosterone level is significantly elevated (>5 nmol/L) — this requires urgent investigation to exclude an androgen-secreting tumour
  • You are considering or using GLP-1 receptor agonists and wish to discuss pre-conception planning

How Settled Is the New Name?

The 2026 consensus was not unanimous — roughly 14% of patients and 24% of health professionals surveyed did not support a name change, and adoption in day-to-day clinical language will take time. It is also, by design, a phased process: the three-year implementation plan covers updates to clinical guidelines, electronic health records, disease classification systems, and patient education materials, with formal integration into the next International Guideline expected in 2028. Until then, "PCOS" and "PMOS" will coexist in clinical use, referring to exactly the same condition.

What the 2026 consensus achieved is broader than the label itself: a documented, majority mandate — built from over two decades of patient and clinician input — that the term "Polycystic Ovary Syndrome" no longer served patients well, and that a name centred on its metabolic and endocrine reality better reflects their lived experience of a systemic condition rather than a localised ovarian disease. That shift in framing is, in itself, clinically significant.

Clinical Perspective from Dr Kazmi

In my endocrinology practice, I see women at all stages of their PMOS journey — those newly diagnosed and frightened by the word "cyst," those who have managed the condition for years without adequate metabolic monitoring, and those who have struggled with fertility treatment without addressing the underlying insulin resistance that makes that treatment harder. The name change matters because language shapes how patients understand their own bodies and how clinicians conceptualise their responsibility. PMOS is not a reproductive inconvenience — it is a metabolic condition that, left inadequately managed, carries real long-term health consequences. My practice approach is to offer every patient with PMOS a comprehensive metabolic assessment at diagnosis and at every review, not just a conversation about periods and fertility. The metabolic health of women with PMOS deserves the same systematic attention we give to cardiovascular risk in men.

Frequently Asked Questions About PCOS / PMOS

These are the questions I am asked most often by patients in clinic, answered directly and without jargon.

There is no single cause. PCOS/PMOS arises from a combination of insulin resistance, excess androgen (male hormone) production by the ovaries and adrenal glands, and a genetic predisposition that runs in families. Insulin resistance is the central driver in most women — high insulin levels push the ovaries to overproduce androgens, which disrupts ovulation and drives the symptoms you notice. It is not caused by anything you did, and it is not caused by diet alone.

PCOS has a strong genetic component. If your mother or sister has it, your own risk is significantly higher, and multiple genes are thought to be involved alongside environmental and metabolic factors. That said, having a family history does not guarantee your daughter will develop it, and there is no single genetic test that predicts it. Early awareness helps — if there is a family history, irregular periods or early acne/hirsutism in a daughter is worth discussing with a doctor rather than waiting.

PCOS/PMOS cannot currently be cured, but it can be very well controlled. It is a lifelong metabolic tendency rather than a disease that switches on and off — the underlying insulin resistance and androgen sensitivity generally persist for life, even during periods when your cycles are regular and symptoms are quiet. That is why ongoing monitoring matters even once things feel "settled." The goal of treatment is long-term control of symptoms and metabolic risk, not a one-off fix.

Yes — the large majority of women with PCOS do conceive, though it may take longer or need medical help with ovulation. PCOS is one of the most common but also most treatable causes of infertility, because the underlying problem is usually anovulation (not ovulating) rather than a structural issue with the ovaries or tubes. First-line treatment is weight optimisation where relevant, followed by ovulation induction with letrozole, with metformin added in some cases. IVF is rarely needed as a first step.

Not necessarily. Metformin is used to improve insulin sensitivity and its role often changes over time — some women take it long-term for metabolic protection, others use it during a specific phase such as trying to conceive, and some are able to stop once weight, cycle regularity, and insulin markers have improved substantially through lifestyle change. This should always be a decision made with your prescribing doctor based on repeat bloodwork, not stopped abruptly on your own.

This is genuine physiology, not a lack of willpower. Insulin resistance in PCOS promotes fat storage — particularly around the abdomen — and blunts the normal appetite-regulating hormone signals, meaning you can feel hungrier and burn calories at a lower basal rate than someone without PCOS, even eating the same diet. This is why generic "eat less, move more" advice so often fails. Effective plans usually combine a lower-glycaemic diet, resistance training, and, where indicated, medication (metformin or a GLP-1 agonist) that directly addresses the insulin resistance driving the weight gain.

Very likely, if it developed gradually alongside irregular periods. Excess androgens are directly responsible for hirsutism (facial/body hair growth), androgenic alopecia (scalp hair thinning, especially at the crown/temples), and persistent jawline or chest acne that doesn't respond to standard skincare. These symptoms typically improve — though slowly, over 6–12 months — with treatments that lower androgen levels or block their effect, such as an anti-androgenic contraceptive pill, spironolactone, or metformin.

Yes. "Lean PCOS" accounts for a meaningful proportion of cases and is genuinely under-recognised, partly because clinicians sometimes assume PCOS only affects women with a higher BMI. Insulin resistance can be present even at a normal weight — it is about how your body handles insulin, not just how much you weigh. If you have irregular cycles, hyperandrogenism, or polycystic ovarian morphology, the diagnosis and metabolic risks apply regardless of your weight, and metabolic screening (glucose, lipids) is still recommended.

No. Diagnosis requires two of three Rotterdam criteria — irregular ovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. If you already have irregular cycles plus blood or clinical signs of excess androgen, that is sufficient for diagnosis without a scan. An ultrasound is one route to diagnosis, not a mandatory one, and it is generally not recommended in the first 8 years after your first period, when polycystic-looking ovaries are common and not necessarily pathological.

For most women, yes — the combined pill is a well-established, first-line long-term option for cycle regulation, endometrial protection, and reducing acne/hirsutism, and it can generally be continued for years with periodic review of blood pressure and cardiovascular risk factors. It manages symptoms rather than treating the underlying insulin resistance, so it should ideally sit alongside — not instead of — metabolic management (diet, activity, metformin where indicated). Choice of pill matters: anti-androgenic progestogens (e.g. drospirenone) are generally preferred in PCOS.

For many women, a sustained 5–10% weight loss and regular resistance/aerobic exercise meaningfully improves or even resolves irregular cycles, androgen levels, and insulin resistance — this is genuinely the single most effective intervention available. However, "alone" is doing a lot of work in that question: many women need medical support (metformin, an anti-androgen, or a GLP-1 agonist) to achieve and sustain that weight change, because PCOS itself makes weight loss physiologically harder. Lifestyle change and medication are not competing options — they usually work best together.

The reproductive features — irregular periods, ovulation problems — naturally resolve at menopause because ovulation stops altogether. However, the underlying insulin resistance and elevated cardiometabolic risk (type 2 diabetes, dyslipidaemia, cardiovascular disease) generally persist and can become more prominent after menopause as protective oestrogen declines. Women with a history of PCOS should continue metabolic screening (glucose, lipids, blood pressure) well beyond their reproductive years — this is not a condition you "age out of" from a health-risk perspective.

GLP-1 receptor agonists (semaglutide, tirzepatide) can be an effective, medically supervised option for women with PCOS and a BMI in the obesity or higher-overweight range, particularly where lifestyle measures and metformin haven't achieved enough weight loss. They are not currently a formal first-line PCOS treatment in guidelines, and they are not suitable in pregnancy or if you might conceive imminently — improved insulin sensitivity can restore ovulation unexpectedly, so reliable contraception and a clear stop-before-conception plan are essential. Never self-source these medications online without medical supervision.

Not necessarily on its own. Polycystic ovarian morphology on ultrasound is common — seen in roughly 1 in 5 women of reproductive age — and by itself is not a diagnosis of PCOS/PMOS. If you have regular ovulatory cycles and no clinical or biochemical signs of excess androgen, you likely do not meet the Rotterdam criteria (which need 2 of the 3 features). This scan finding alone, in isolation, does not require treatment, though it is worth noting if you develop symptoms later.

Diagnosis in adolescence needs particular care because irregular cycles and polycystic-looking ovaries are both common and often normal in the first few years after a first period. ESHRE 2023 recommends that a firm diagnosis in adolescents requires both irregular cycles persisting beyond 2 years post-menarche and clear clinical or biochemical hyperandrogenism — ultrasound is not used for diagnosis in this age group. Teenagers who don't yet meet full criteria but show risk features can be labelled "at increased risk" and monitored, rather than formally diagnosed or left unmonitored.

References

Primary sources cited in this article, listed in order of appearance.

  1. 1

    Teede HJ, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026.

    View Source
  2. 2

    Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome (ESPART Trial). N Engl J Med. 2014;371(2):119–129.

    View Source
  3. 3

    Teede HJ, Tay CT, Laven JJE, et al. International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (ESHRE 2023). Hum Reprod. 2023;38(9):1655–1679.

    View Source
  4. 4

    Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial). N Engl J Med. 2023;389(24):2221–2232.

    View Source
  5. 5

    Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 Trial). N Engl J Med. 2022;387(3):205–216.

    View Source
DK

Dr Syed Kashif Hussain Kazmi

Consultant Endocrinologist, Diabetologist & Obesity Medicine Physician
Naas Cardiology & Endocrinology Clinic, Co. Kildare

MRCPI FRCP Glasgow CCT UK IMC Registered

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making any health decisions. This website does not provide remote diagnosis, prescription, or telemedicine services.

Further Reading

Concerned About PMOS or Hormonal Health?

Dr Kazmi offers comprehensive endocrinology assessments including full metabolic screening, hormonal profiling, and individualised treatment planning for women with PMOS.

Book an Appointment